The estimated worldwide prevalence of dementia was 35.6 million in 2010 and is expected to almost double within the next 20 years.[@b1] Dementia may be accompanied by physical aggression, anxiety, hallucinations, and behavioral problems, which are referred to as behavioral and psychological symptoms of dementia.[@b2] For management of these symptoms, antipsychotic agents (APs) are frequently prescribed.[@b3],[@b4] Because the second-generation APs are considered to have fewer side effects than first-generation APs, they are now more widely used in patients with behavioral and psychological symptoms of dementia than first-generation APs.[@b5],[@b6] In recent years, however, data from observational studies have raised concerns about the safety of this practice.[@b7]--[@b11] Of particular note, it has been suggested that the risk of sudden cardiac death associated with second-generation APs may be at least as high as that for first-generation APs.[@b12] Moreover, use of APs in people with dementia has been associated with increased risk of stroke and acute myocardial infarction, but prior studies did not differentiate between first- and second-generation APs.[@b13],[@b14]

In addition to using APs to treat behavioral problems in elderly patients with dementia, elderly persons without dementia are often prescribed APs for conditions such as anxiety, depression, or insomnia; however, the outcomes associated with AP use in this particular group have not been well investigated, and it is not known if risks differ for patients with and without dementia. Moreover, several APs are considered to pose greater risk of adverse outcomes for patients with established cardiovascular disease (CVD) than for patients without CVD, but head-to-head comparisons of individual APs in patients with and without CVD are sparse.[@b15] To further address these issues, we investigated the risk of major adverse cardiovascular events (MACE) and noncardiovascular mortality associated with individual APs in a Danish population with and without diagnosed dementia and with and without CVD.

Methods
=======

The study was approved by the Danish Data Protection Agency (2007-58-0015/local j.nr. GEH-2014-012 I-Suite nr: 02720). Register-based studies in which persons cannot be identified do not need ethics approval in Denmark. All Danish citizens are medically covered by a tax-financed system that provides each citizen with equal health care free of copayment. For administrative purposes, the government has kept records of all hospitalizations (in-hospital and outpatient visits) since 1978 (in the Danish National Patient Registry) and records of all prescription claims from Danish pharmacies since 1995 (in the Danish Register of Medicinal Product Statistics). Furthermore, registration of all births and deaths, including dates of occurrence, has been complete for all citizens since 1968 (in the National Population Register). Because all Danish citizens are given a permanent personal civil registration number at time of birth or immigration, they can be followed up by individual-level linkage of the registers.

Population and Comorbidities
----------------------------

For the present study, we included all persons in Denmark between 1997 and 2011 who were aged ≥70 years at the time when they claimed their first prescription of antipsychotic medication and who had previously been treatment-naïve (ie, allowing for a look back to 1995, when the Danish Register of Medicinal Product Statistics was established). We identified comorbidities throughout the whole observational period by continuous screening of the Danish National Patient Register. Because most diagnoses were for chronic conditions, people were classified as having the disease from the first day of diagnosis. For all diagnoses but dementia, schizophrenia, and Parkinson's disease, only validated in-hospital diagnoses were considered.[@b16] In addition to previously validated chronic comorbid diagnoses, we retrieved information on acute delirium based on in-hospital diagnoses. Because the diagnoses of dementia, Parkinson's disease, and schizophrenia are often based on outpatient visits, diagnoses from both in-hospital and outpatient visits were considered for these comorbidities.

Outcomes
--------

The primary outcomes were MACE, comprising the first occurring nonfatal acute myocardial infarction (*International Classification of Diseases, 10th revision* \[ICD-10\] code I21) or nonfatal ischemic stroke (ICD-10 codes I63 and I64 \["I64" denotes unspecified stroke, of which the majority are of ischemic origin\])[@b17] and cardiovascular mortality (ICD-10 codes I00 to I99) and non--cardiovascular-related mortality (causes of mortality were obtained from the Danish Causes of Death Register).

Pharmacotherapy
---------------

From the National Register of Medicinal Product Statistics, we identified exposure to the individual APs outlined in Table[1](#tbl1){ref-type="table"}. For these agents and for vitamin K antagonists (B01AA03), clopidogrel (B01AC04), low-dose aspirin (B01AC06), and loop diuretics (C03CA01, C03CA02), treatment was updated continuously, that is, patients were considered to be exposed only while covered by claimed prescriptions. To determine treatment length and average daily dosages, up to 3 consecutive prescriptions were considered in a retrospective manner. We created an algorithm for each agent in which minimum, maximum, and typical daily dosages of used medication were defined. For patients' first claimed prescriptions, the typical daily dosage was assigned, and treatment length was calculated by dividing the amount of claimed medications by that daily dosage. For patients who were covered by a previous prescription at the time of claiming a new prescription, the daily dosage was reset, and a new daily dosage was calculated as the amount of claimed medications during the previous period divided by time between prescription claims (based on up to 3 previous prescriptions without treatment breaks). If calculated dosages exceeded the predefined highest daily dosages, patients were assigned the maximum dosages, and exceeding tablets were assumed to be stored and consumed during the immediate period following the end of the last prescription.

###### 

Classification of the Different Antipsychotic Agents

  Name              ATC Code   Generation
  ----------------- ---------- ------------
  Chlorprothixen    N05AF03    First
  Flupentixol       N05AF01    First
  Haloperidol       N05AD01    First
  Levomepromazine   N05AA02    First
  Olanzapine        N05AH03    Second
  Risperidone       N05AX08    Second
  Quetiapine        N05AH04    Second
  Ziprasidone       N05AE04    Second

For other medications (ie, dementia medications \[ATC code N06DA\], beta blockers \[C07\], thiazides \[C03A\], calcium channel blockers \[C08\], digoxin \[C01AA\], renin-angiotensin system inhibitors \[C09\], aldosterone blockers \[C03D\], and statins \[C10AA\]), treatment status was updated every 30 days for the whole observational period. Persons were considered to be in treatment with the different medications if they claimed at least 1 prescription during the preceding 4 months (this pragmatic method was applied because of computational limitations).

Statistics
----------

All patients were followed from the date of first claimed prescription until date of death, emigration, or December 31, 2011. The incidence rate ratios (IRRs) associated with exposure to APs were analyzed using multivariable Poisson regression models. The following variables were included as time-dependent variables: treatment with antipsychotic medications; all comorbidities (schizophrenia, Parkinson's disease, dementia, acute delirium, prior cerebrovascular disease, heart failure, acute myocardial infarction, peripheral vascular disease, chronic obstructive pulmonary disease, atrial fibrillation, moderate or severe renal disease, diabetes, cancer, and cancer with metastases; for ICD-10 codes, see Table[2](#tbl2){ref-type="table"}); age; and use of warfarin, aspirin, clopidogrel, loop diuretics, thiazides, renin-angiotensin system blockers, aldosterone antagonists, statins, beta blockers, calcium channel blockers, or digoxin. All models were adjusted for the aforementioned variables and for actual calendar year and sex. Use of antipsychotic medications was included as a time-dependent multilevel categorical variable for which people using \>1 medication for a given time were grouped in a separate *use of multiple medication* category. People who were not covered by a claimed prescription were assigned to a *no treatment* category. For all comparisons, use of risperidone as monotherapy served as the referent group (because this group was the largest quantitatively). We performed 2 separate types of analyses. In the first, we created 3 different categorical variables for antipsychotic use according to time elapsed since first treatment because time dependency for risks was present (*P* for interaction between time elapsed and associated risks \<0.0001; use of medications was split into the first 30 days, 31 to 365 days, and \>365 days after treatment initiation). After having explored the IRRs among different medications in different time periods, the differences appeared to be rather small between the periods; therefore, in subsequent models, we included a variable reflecting only time since first treatment initiation to account for time dependency in risks. In the second models, we tested for effect modification between the different treatment groups and prevalent dementia (diagnosis or use of dementia medications) and CVD (myocardial infarction, congestive heart failure, stroke, or peripheral vascular disease) by inclusion of an interaction term between the categorical treatment variable and CVD or dementia, respectively. Because these were highly significant, we created a categorical dummy variable stratifying use of medications by the prevalence of the different diseases. All analyses were done in SAS version 9.4 (SAS Institute). A 2-sided *P*\<0.05 was considered statistically significant.

###### 

ICD-10 Codes for Various Medical Conditions

  Condition                               ICD-10
  --------------------------------------- ------------------------------------------------------------------------------
  Dementia                                F00, F01, F02, F03, F05.1, G30
  Schizophrenia                           F20
  Parkinson's disease                     G20
  Acute delirium                          F05
  Ischemic heart disease                  I20, I23, I24, I25
  Cerebrovascular disease                 I60 to I69, G45, G46
  Acute myocardial infarction             I21, I22, I23
  Heart failure                           I50, I42, I110, I13.0, I13.2
  Atrial fibrillation                     I48
  Peripheral artery disease               I70 to I74
  Chronic obstructive pulmonary disease   J40 to 47, J60 to 67, J68.4, J70.1, J70.3, J84.1, J92.0, J96.1, J98.2, J98.3
  Cancer                                  C00 to C75, C81 to 96
  Metastases                              C76 to C80
  Renal disease                           N00 to 06, N07, N11, N17 to 19, R34, I12, I13, Q61
  Diabetes                                Treatment with glucose-lowering medication (ATC code A10)

ICD-10 indicates *International Classification of Diseases, 10th Revision*.

Results
=======

We identified 91 774 persons (mean age 82±7 years, 35 474 \[39%\] were men). Numbers of those ever exposed to the different APs are presented in Table[3](#tbl3){ref-type="table"}, along with the baseline characteristics for different exposure groups. The different exposure groups had comparable age, sex, and comorbidity burdens, although patients receiving levomepromazine and haloperidol had higher prevalence of cancers (≈30% versus 10% for the other groups).

###### 

Baseline Characteristics of Study Population

                                              Haloperidol (n=20 873)   Flupentixol (n=10 807)   Levopromazine (n=16 127)   Chlorprothixen (n=7762)   Quetiapine (n=12 854)   Risperidone (n=28 161)   Olanzapine (n=16 102)   Ziprasidone (n=500)
  ------------------------------------------- ------------------------ ------------------------ -------------------------- ------------------------- ----------------------- ------------------------ ----------------------- ---------------------
  Age, y (SD)                                 83 (7)                   79 (6)                   80 (7)                     79 (7)                    82 (6)                  84 (7)                   82 (7)                  81 (7)
  Sex, male (%)                               9122 (44)                3081 (29)                7105 (44)                  2843 (37)                 5149 (40)               10 268 (36)              5589 (35)               170 (34)
  Cerebrovascular disease (%)                 5193 (25)                2544 (24)                3266 (20)                  1647 (21)                 3338 (26)               7241 (26)                4050 (25)               123 (25)
  Heart failure (%)                           3378 (16)                1763 (16)                3227 (20)                  1203 (16)                 1554 (12)               4064 (14)                2357 (15)               76 (15)
  Acute myocardial infarction (%)             1837 (9)                 1091 (10)                1557 (10)                  680 (9)                   995 (8)                 2144 (8)                 1203 (7)                32 (6)
  Peripheral arterial disease (%)             1428 (7)                 705 (7)                  1336 (8)                   529 (7)                   660 (5)                 1460 (5)                 818 (5)                 24 (5)
  Chronic obstructive pulmonary disease (%)   2737 (13)                1822 (17)                4369 (27)                  1381 (18)                 1377 (11)               2855 (10)                1795 (11)               51 (10)
  Cancer (%)                                  6097 (29)                2072 (19)                4826 (30)                  1447 (19)                 1731 (13)               3292 (12)                2344 (15)               48 (10)
  Cancer with metastases (%)                  1948 (9)                 384 (4)                  1348 (8)                   238 (3)                   199 (2)                 416 (1)                  452 (3)                 5 (1)
  Atrial fibrillation (%)                     3432 (15)                768 (7)                  1860 (11)                  750 (9)                   1799 (13)               1065 (4)                 1866 (12)               50 (10)
  Parkinson's disease (%)                     483 (2)                  298 (3)                  335 (2)                    197 (3)                   1516 (12)               889 (3)                  1050 (7)                15 (3)
  Acute delirium (%)                          1357 (7)                 212 (2)                  210 (1)                    175 (2)                   902 (7)                 1473 (5)                 720 (4)                 15 (3)
  Schizophrenia (%)                           71 (0.3)                 25 (0.2)                 45 (0.3)                   60 (1)                    128 (1)                 287 (1)                  288 (2)                 15 (3)
  Diabetes (%)                                2226 (11)                785 (7)                  1552 (10)                  720 (9)                   1309 (10)               2728 (10)                1435 (9)                45 (9)
  Renal disease (%)                           1044 (5)                 501 (5)                  854 (5)                    409 (5)                   525 (4)                 1073 (4)                 689 (4)                 23 (5)
  Dementia diagnosis (%)                      1638 (8)                 154 (1)                  374 (2)                    235 (3)                   2394 (19)               3357 (12)                1718 (11)               83 (17)
  Treatment with dementia medications (%)     3058 (15)                813 (8)                  903 (6)                    669 (9)                   4625 (36)               6688 (24)                3550 (22)               163 (33)
  Statin treatment (%)                        2051 (10)                939 (9)                  1194 (7)                   977 (13)                  2057 (16)               2488 (9)                 1224 (8)                44 (9)
  RAS inhibitors (%)                          3832 (18)                1945 (18)                2811 (17)                  1604 (21)                 2801 (22)               4869 (17)                2426 (15)               68 (14)
  Calcium channel blockers (%)                3095 (15)                1816 (17)                2589 (16)                  1277 (16)                 1908 (15)               3862 (14)                2104 (13)               73 (15)
  Beta blockers (%)                           3411 (16)                1673 (15)                2098 (13)                  1185 (15)                 2242 (17)               4256 (15)                2125 (13)               57 (11)
  Digoxin (%)                                 2839 (14)                869 (8)                  2117 (13)                  608 (8)                   1146 (9)                3231 (11)                1699 (11)               38 (8)
  Thiazides (%)                               3445 (17)                1929 (18)                2596 (16)                  1286 (17)                 2283 (18)               4715 (17)                2642 (16)               86 (17)
  Aldosterone blockers (%)                    1269 (6)                 361 (3)                  1224 (8)                   259 (3)                   546 (4)                 1326 (5)                 699 (4)                 17 (3)
  Aspirin (%)                                 6874 (33)                2850 (26)                4525 (28)                  2187 (28)                 4678 (36)               9746 (35)                5151 (32)               168 (34)
  Clopidogrel (%)                             355 (2)                  86 (1)                   152 (1)                    100 (1)                   286 (2)                 370 (1)                  186 (1)                 2 (0.4)
  Warfarin (%)                                834 (4)                  286 (3)                  538 (3)                    256 (3)                   557 (4)                 994 (4)                  471 (3)                 13 (3)

Baseline characteristics for different antipsychotic medication users. Numbers are presented as counts (%) for discrete variables and means (SD) for continuous variables. Characteristics were obtained at first day of treatment; thus groups are not exclusive. RAS indicates renin-angiotensin system.

Total exposure time, MACE, and noncardiovascular mortality for each treatment group are given in Tables[4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"}. Crude event rates were lowest for flupentixol and chlorprothixen compared with the other AP groups. As seen in the tables, for all agents, we observed a highly increased incidence rate of MACE and noncardiovascular mortality during the first month after initiation, with a subsequent decline for longer treatment durations. Associated adjusted IRRs were increased for treatment with levomepromazine or haloperidol and treatment with multiple medications, whereas treatment with flupentixol, ziprasidone, chlorprothixen, or quetiapine was associated with a significantly lower IRR compared with treatment with risperidone, as shown in Figure[1](#fig01){ref-type="fig"} (MACE) and Figure[2](#fig02){ref-type="fig"} (noncardiovascular mortality). For longer treatment duration, levomepromazine and use of multiple medications were no longer associated with increased risks compared with risperidone monotherapy (Figures[1C](#fig01){ref-type="fig"} and [2C](#fig02){ref-type="fig"}). The risks associated with use of different antipsychotic medications differed for patients with and without CVD and were greater among patients with established CVD (*P* for interaction between treatment group and CVD \<0.00001) (Figure[3](#fig03){ref-type="fig"}. Similarly, the risks were slightly higher among patients without established dementia compared with patients with dementia (*P* for interaction between treatment group and dementia \<0.0001) (Figure[4](#fig04){ref-type="fig"}.

###### 

Numbers of Major Adverse Cardiovascular Events, Exposure Time, and Crude Incidence Rates for Different Antipsychotic Agents

                                                                   Events/Person-Years   Unadjusted Incidence Rate (Per 100 Person-Years)
  ---------------------------------------------------------------- --------------------- --------------------------------------------------
  Associated risks for the first 30 days after initiation                                
   Risperidone                                                     842/1765              47.7 (44.6 to 51.0)
   Flupentixol                                                     142/859               16.5 (14.0 to 19.5)
   Chlorprothixen                                                  132/460               28.7 (24.2 to 34.0)
   Levomepromazine                                                 1162/717              162 (153 to 172)
   Haloperidol                                                     1250/1340             93.3 (88.3 to 98.6)
   Ziprasidone                                                     3/30                  10.1 (3.2 to 31.2)
   Quetiapine                                                      284/952               29.8 (26.5 to 33.5)
   Olanzapine                                                      428/1106              38.7 (35.2 to 42.5)
   Multiple medications                                            143/142               101 (85 to 119)
  Associated risks for the first 31 to 365 days after initiation                         
   Risperidone                                                     2294/10 523           21.8 (20.9 to 22.7)
   Flupentixol                                                     397/3577              11.1 (10.1 to 12.2)
   Chlorprothixen                                                  168/1466              11.5 (9.9 to 13.3)
   Levomepromazine                                                 426/2179              19.5 (17.8 to 21.5)
   Haloperidol                                                     1471/3834             38.4 (36.5 to 40.4)
   Ziprasidone                                                     3/16                  19.3 (6.2 to 59.9)
   Quetiapine                                                      925/6234              14.8 (13.9 to 15.8)
   Olanzapine                                                      1151/6645             17.3 (16.3 to 18.4)
   Multiple medications                                            172/621               27.7 (23.9 to 32.2)
  Associated risks for the first \>365 days after initiation                             
   Risperidone                                                     2516/16 231           15.5 (14.9 to 16.1)
   Flupentixol                                                     488/5676              5.6 (7.9 to 9.4)
   Chlorprothixen                                                  288/3350              8.6 (7.7 to 9.6)
   Levomepromazine                                                 515/4603              11.2 (10.3 to 12.2)
   Haloperidol                                                     602/2908              20.7 (19.1 to 22.4)
   Ziprasidone                                                     31/265                11.7 (8.2 to 16.6)
   Quetiapine                                                      1001/8995             11.1 (10.5 to 11.8)
   Olanzapine                                                      1635/13 032           12.5 (12.0 to 13.2)
   Multiple medications                                            130/1086              12.0 (10.1 to 14.2)

###### 

Numbers of Noncardiovascular Mortality, Exposure Time, and Crude Incidence Rates for Different Antipsychotic Agents

                                                                   Events/Person-Years   Unadjusted Incidence Rate (Per 100 Person-Years)
  ---------------------------------------------------------------- --------------------- --------------------------------------------------
  Associated risks for the first 30 days after initiation                                
   Risperidone                                                     630/1809              34.8 (32.2 to 37.7)
   Flupentixol                                                     99/867                11.4 (9.4 to 13.9)
   Chlorprothixen                                                  116/469               24.8 (20.6 to 29.7)
   Levomepromazine                                                 2052/750              274 (262 to 286)
   Haloperidol                                                     2365/1411             168 (161 to 175)
   Ziprasidone                                                     12/31                 39.1 (22.2 to 68.8)
   Quetiapine                                                      281/982               28.6 (25.5 to 32.2)
   Olanzapine                                                      472/1136              41.6 (38.0 to 45.5)
   Multiple medications                                            239/148               162 (143 to 184)
  Associated risks for the first 31 to 365 days after initiation                         
   Risperidone                                                     1900/10 949           17.4 (16.6 to 18.2)
   Flupentixol                                                     293/3671              8.0 (7.1 to 9.0)
   Chlorprothixen                                                  122/1506              8.1 (6.8 to 9.7)
   Levomepromazine                                                 580/2292              25.3 (23.3 to 27.4)
   Haloperidol                                                     2109/4254             49.6 (47.5 to 51.7)
   Ziprasidone                                                     3/18                  16.8 (5.4 to 52.0)
   Quetiapine                                                      1009/6552             15.4 (14.5 to 16.4)
   Olanzapine                                                      1064/6896             15.4 (14.5 to 16.4)
   Multiple medications                                            236/656               36.0 (31.7 to 40.9)
  Associated risks for the first \>365 days after initiation                             
   Risperidone                                                     2704/17 604           15.4 (14.8 to 16.0)
   Flupentixol                                                     339/6098              5.6 (5.0 to 6.2)
   Chlorprothixen                                                  226/3605              6.3 (5.5 to 7.1)
   Levomepromazine                                                 481/4992              9.6 (8.8 to 10.5)
   Haloperidol                                                     568/3167              18.0 (16.5 to 19.5)
   Ziprasidone                                                     49/284                17.3 (13.0 to 22.8)
   Quetiapine                                                      1631/9916             16.4 (15.7 to 17.3)
   Olanzapine                                                      1850/14 275           13.0 (12.4 to 13.6)
   Multiple medications                                            185/1165              15.9 (13.8 to 18.3)

![Multivariable-adjusted risks of MACE for different treatment regimens in different time periods after treatment initiation: (A) first 30 days, (B) 31 to 365 days, (C) \>365 days. MACE indicates major adverse cardiovascular events.](jah30004-e001666-f1){#fig01}

![Multivariable-adjusted risks of noncardiovascular mortality for different treatment regimens in different time periods after treatment initiation: (A) first 30 days, (B) 31 to 365 days, (C) \>365 days.](jah30004-e001666-f2){#fig02}

![Multivariable-adjusted risks of (A) MACE and (B) noncardiovascular mortality stratified by prevalent CVD. CV indicates cardiovascular; CVD, cardiovascular disease; MACE, major adverse cardiovascular events.](jah30004-e001666-f3){#fig03}

![Multivariable-adjusted risks of (A) MACE and (B) noncardiovascular mortality stratified by prevalent dementia. CV indicates cardiovascular; MACE, major adverse cardiovascular events.](jah30004-e001666-f4){#fig04}

Discussion
==========

In this Danish study of all persons without prior use of APs who were aged ≥70 years, we investigated the association between different APs and risks of MACE and noncardiovascular mortality. In general, we observed that use of haloperidol or levomepromazine and treatment with multiple medications were associated with similar or greater IRRs than use of risperidone, whereas treatment with flupentixol, ziprasidone, chlorprothixen, or quetiapine was associated with significantly lower IRRs compared with treatment with risperidone. The absolute event rates were highest shortly after treatment initiation and declined with long-term use.

Safety of APs in Elderly Persons
--------------------------------

After findings of increased risk of cerebrovascular events associated with use of second-generation APs,[@b10],[@b18],[@b19] the US Food and Drug Administration (FDA) issued a warning in 2005 against use of second-generation APs in dementia.[@b18],[@b20] In 2008, the FDA extended this warning to include use of first-generation APs in dementia.[@b21] Several studies have since demonstrated increased mortality with use of APs in dementia,[@b8],[@b10],[@b22] and some studies have shown increased mortality in elderly patients regardless of dementia status.[@b9],[@b11],[@b19] Previous studies have also suggested that the use of APs is associated with increased risk of myocardial infarction among older patients with treated dementia[@b13] and that exposure to APs may be a trigger for stroke.[@b11] Furthermore, a Cochrane review estimated the risk of cerebrovascular events to be \>3-fold higher in risperidone- versus placebo-treated elderly patients with dementia.[@b23] Our observations suggest that medications belonging to the second- and first-generation classes of APs may be associated with more or less comparable risk in elderly patients with or without dementia, although flupentixol, chlorprothixen, and quetiapine may be particularly associated with lower MACE and mortality rates than risperidone.

For all drugs, we found that the incidence rates of MACE and noncardiovascular mortality were highest during the first 30 days of treatment and declined with longer exposure time. This finding is consistent with the findings of other studies.[@b11],[@b22],[@b24] When elderly patients are prescribed APs, it may be due to neuropsychiatric symptoms in dementia or to delirium as part of a somatic disease that carries a high mortality risk. Because we were unable to accurately control for several diseases in our study, it cannot be excluded that the higher risks observed, especially among nondemented elderly people who were treated, may be partly due to confounding by indication. Delirium, however, is an acute disease with high short-term mortality; therefore, associations with long-term use may be less prone to confounding than the analyses of short-term use. Worth emphasizing in this context is that the relative risk of mortality with levomepromazine and haloperidol shortly after treatment initiation was higher than that observed for other APs. A very high proportion of patients using these drugs had diagnosed cancer; therefore, we cannot rule out that the IRR for the first period after treatment initiation was driven by confounding by indication. Even when excluding patients with a preexisting cancer, haloperidol has been shown to be associated with the highest risk of death among APs users in nursing homes.[@b24]

First- Versus Second-Generation APs
-----------------------------------

Second-generation APs have been promoted for having a low risk of extrapyramidal symptoms compared with first-generation APs. Previous studies suggest that both first- and second-generation APs can lower blood pressure, leading to increased risk of falls and to a varying extent to prolonged QT interval, which might lead to arrhythmia and death.[@b25]--[@b28] Another problem related to second-generation APs is adverse influence on glucose metabolism, diabetes, and blood lipid composition, leading to increased cardiovascular risks with long-term use.[@b29],[@b30]

Several prior observational studies have compared the safety of first- versus second-generation APs[@b6],[@b8],[@b9],[@b11],[@b22],[@b19],[@b31]--[@b33] and generally have indicated that the risk of death and/or MACE when using second-generation APs is at least as high as that for first-generation APs.[@b21] At least 1 retrospective cohort study has suggested that in older adults with dementia, second- and first-generation APs were associated with comparable risks of ischemic stroke.[@b31] A larger retrospective cohort study in 2009 also suggested a comparable dose-related increased risk of sudden cardiac death for first- and second-generation APs.[@b12]

Strengths and Limitations of the Study
--------------------------------------

The main strength and novelty of this study is that we compared MACE and noncardiovascular mortality risk among individual APs across the first and second generations in a rather large group of patients aged ≥70 years. Moreover, because medical care is offered to all Danish citizens without copayment and because medications are reimbursed by the government, selection bias related to socioeconomic status and, for example, prior participation in the labor market is likely less pronounced compared with many other observational studies. Another strength of our study was the sample size, which allowed us to examine the effect of individual drugs, although it must be acknowledged that we might still have lacked power to firmly conclude anything about some of the individual drugs (particularly ziprasidone). Some limitations, however, merit consideration. We lacked data on several clinical variables including blood pressure, hematological profiles, electrocardiograms, and indication for treatment. All of these variables may have influenced clinicians' decisions of whether to prescribe a particular agent. Our data must be interpreted with great caution, bearing these limitations in mind.

Conclusion and Clinical Implications
====================================

There is an important but limited role for antipsychotic treatment of severe neuropsychiatric symptoms.[@b23] Our study demonstrated high incidence rates of MACE and noncardiovascular mortality associated with use of individual APs in elderly persons with or without dementia and with and without CVD. This underscores that APs should be used with caution in elderly patients, regardless of dementia status, at the lowest possible dose and for shortest possible time. A particular focus on risks and benefits is warranted among people with prevalent CVD because these patients seem to have the highest risks associated with APs. Our study further suggested some diversity in risks associated with individual APs but no systematic differences between first- and second-generation APs. Randomized placebo-controlled studies are warranted to confirm our findings and to identify the safest agents. Until then, the antipsychotic benefit in people with and without dementia must be considered against the risks of adverse events. Finally, in Denmark, restrictions on the use of APs are focused predominantly on people with dementia. Our study warrants a broader focus on elderly people in general.
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